Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Immunol. 2011 May 23;187(1):200–211. doi: 10.4049/jimmunol.1100647

Figure 2. Mass spectrometric characterization of piperacillin haptens formed on albumin in vitro and isolated from plasma of patients undergoing piperacillin treatment.

Figure 2

Representative MS/MS spectrum of the albumin peptide 182LDELRDEGKASSAK195 modified at Lys190 with (A) the cyclized and hydrolyzed piperacillin haptens and (B) the hydrolyzed desethyl piperacillin hapten. Characteristic fragment ions derived from partial cleavage of the hapten are circled. (C) Epitope profile showing the lysine residues of albumin modified in vivo with the cyclized and hydrolyzed piperacillin and desethyl piperacillin haptens.